Trial Profile
A PHASE 3, RANDOMIZED, DOUBLE BLIND, CONTROLLED, MULTI CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Diclofenac (Primary) ; Tanezumab (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Pfizer
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 12 Jul 2013 Results published in the Annals of the Rheumatic Diseases.
- 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.